Multiscale Tumor Spatiokinetic Model for Intraperitoneal Therapy
暂无分享,去创建一个
[1] Bin Chen,et al. Predictive Models of Diffusive Nanoparticle Transport in 3-Dimensional Tumor Cell Spheroids , 2013, The AAPS Journal.
[2] Jacek Waniewski,et al. Computer simulations of osmotic ultrafiltration and small-solute transport in peritoneal dialysis: a spatially distributed approach. , 2012, American journal of physiology. Renal physiology.
[3] Ze Lu,et al. Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. , 2011, Nanomedicine.
[4] J. Au,et al. Abstract 5453: Drug transport in peritoneal tumors during intraperitoneal therapy – evaluation by computational model , 2011 .
[5] J. Au,et al. Intraperitoneal therapy for peritoneal cancer. , 2010, Future oncology.
[6] J. Au,et al. Delivery of siRNA Therapeutics: Barriers and Carriers , 2010, The AAPS Journal.
[7] Michael F. Flessner,et al. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence , 2010, Nature Reviews Clinical Oncology.
[8] Beom Soo Shin,et al. Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy , 2009, Journal of Pharmacology and Experimental Therapeutics.
[9] Ze Lu,et al. Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer , 2008, Journal of Pharmacology and Experimental Therapeutics.
[10] D. Rockey,et al. Effect of the nitric oxide donor V-PYRRO/NO on portal pressure and sinusoidal dynamics in normal and cirrhotic mice. , 2008, American journal of physiology. Gastrointestinal and liver physiology.
[11] R. Jain,et al. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. , 2008, Cancer research.
[12] J. Au,et al. Tumor Priming Enhances Delivery and Efficacy of Nanomedicines , 2007, Journal of Pharmacology and Experimental Therapeutics.
[13] Ze Lu,et al. Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel , 2007, Pharmaceutical Research.
[14] Ricky T. Tong,et al. Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. , 2007, Cancer research.
[15] Lalit Kumar,et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.
[16] D-S Lee,et al. Flow correlated percolation during vascular remodeling in growing tumors. , 2005, Physical review letters.
[17] M. Flessner,et al. The transport barrier in intraperitoneal therapy. , 2005, American journal of physiology. Renal physiology.
[18] Hanna Parnas,et al. Mathematical modeling and optimization of drug delivery from intratumorally injected microspheres. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] Lei Xu,et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.
[20] W. Sessa,et al. Antiangiogenic therapy: creating a unique "window" of opportunity. , 2004, Cancer cell.
[21] Timothy W Secomb,et al. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. , 2004, Neoplasia.
[22] Jessie L.-S. Au,et al. Drug Delivery and Transport to Solid Tumors , 2003, Pharmaceutical Research.
[23] I. Barasoain,et al. Fast Kinetics of Taxol Binding to Microtubules , 2003, The Journal of Biological Chemistry.
[24] B. Döme,et al. Vascularization of cutaneous melanoma involves vessel co‐option and has clinical significance , 2002, The Journal of pathology.
[25] Rakesh K Jain,et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.
[26] E. Venkatraman,et al. Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Wientjes,et al. Clinical aspects of drug delivery to tumors. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[28] E. Fishman,et al. Tumor transport physiology: implications for imaging and imaging-guided therapy. , 2001, AJR. American journal of roentgenology.
[29] E. Edelman,et al. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. , 2001, Journal of pharmaceutical sciences.
[30] M. Wientjes,et al. Kinetics of P-glycoprotein-mediated efflux of paclitaxel. , 2001, The Journal of pharmacology and experimental therapeutics.
[31] Jessie L.-S. Au,et al. Determinants of Paclitaxel Uptake, Accumulation and Retention in Solid Tumors , 2001, Investigational New Drugs.
[32] B N Bundy,et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Verweij,et al. Measurement of fraction unbound paclitaxel in human plasma. , 2000, Drug metabolism and disposition: the biological fate of chemicals.
[34] M. Wientjes,et al. Computational model of intracellular pharmacokinetics of paclitaxel. , 2000, The Journal of pharmacology and experimental therapeutics.
[35] T. Edition,et al. Formulary for Laboratory Animals , 1999 .
[36] M. Wientjes,et al. Determinants of paclitaxel penetration and accumulation in human solid tumor. , 1999, The Journal of pharmacology and experimental therapeutics.
[37] J Verweij,et al. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. , 1999, Cancer research.
[38] B. Rippe,et al. Clearance of Tracer Albumin from Peritoneal Cavity to Plasma at Low Intraperitoneal Volumes and Hydrostatic Pressures , 1998, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.
[39] M. Wientjes,et al. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. , 1998, Cancer research.
[40] M. Piver,et al. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer. , 1998, Gynecologic oncology.
[41] W. Saltzman,et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. , 1998, Cancer research.
[42] D. Alberts,et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.
[43] W. Mark Saltzman,et al. Chemotherapeutic Drugs Released from Polymers: Distribution of 1,3-bis(2-chloroethyl)-l-nitrosourea in the Rat Brain , 1996, Pharmaceutical Research.
[44] R K Jain,et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.
[45] C. Nicholson. Interaction between diffusion and Michaelis-Menten uptake of dopamine after iontophoresis in striatum. , 1995, Biophysical journal.
[46] R K Jain,et al. Diffusion and partitioning of proteins in charged agarose gels. , 1995, Biophysical journal.
[47] M. Piver,et al. Evaluation of survival after second‐line intraperitoneal cisplatin‐based chemotherapy for advanced ovarian cancer , 1994, Cancer.
[48] K. Bhalla,et al. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. , 1993, Research communications in chemical pathology and pharmacology.
[49] R. Jain,et al. Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. , 1993, Microvascular research.
[50] Maurie Markman. Current status of intraperitoneal therapy for ovarian cancer , 1993, Current opinion in obstetrics & gynecology.
[51] R. Barakat,et al. Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] R K Jain,et al. Determinants of tumor blood flow: a review. , 1988, Cancer research.
[53] J. Levick. Flow through interstitium and other fibrous matrices. , 1987, Quarterly journal of experimental physiology.
[54] S. Howell,et al. Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. , 1987, Cancer research.
[55] M F Flessner,et al. A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat. , 1985, The American journal of physiology.
[56] C. Nicholson,et al. Ion diffusion modified by tortuosity and volume fraction in the extracellular microenvironment of the rat cerebellum. , 1981, The Journal of physiology.
[57] V. Devita,et al. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. , 1980, Cancer research.
[58] D. Collins,et al. Peritoneal dialysis efficiency in relation to body weight , 1966 .
[59] E. Reed,et al. Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer , 2004, Cancer Chemotherapy and Pharmacology.
[60] B. Rippe. What is the role of albumin in proteinuric glomerulopathies? , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[61] J. Au,et al. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[62] A. Verkman,et al. Reduced osmotic water permeability of the peritoneal barrier in aquaporin-1 knockout mice. , 1999, The American journal of physiology.
[63] David Odde. Diffusion inside microtubules , 1998, European Biophysics Journal.
[64] W. Deen. Analysis Of Transport Phenomena , 1998 .
[65] D. Song,et al. Binding of taxol to plastic and glass containers and protein under in vitro conditions. , 1996, Journal of pharmaceutical sciences.
[66] R K Jain,et al. Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. , 1991 .
[67] P. Sevelda,et al. First experiences with intraperitoneal chemotherapy in ovarian cancer. , 1990, European journal of gynaecological oncology.
[68] R K Jain,et al. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. , 1989, Microvascular research.